CHICAGO — Visual acuity and anatomical improvements were achieved at all dose levels of nesvacumab combined with aflibercept in patients with diabetic macular edema or neovascular age-related macular ...

In the Phase Ib JADE trial, OLN324 demonstrated both faster and greater retinal drying versus Vabysmo in patients with DME, ...

Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases ...

Acute lung injury caused by cell death, high and potentially toxic concentrations of oxygen (hyperoxia), and the resulting excess fluid in the lungs (pulmonary edema), may be controlled by modulating ...

Role of VEGF and VEGFR2 single nucleotide polymorphisms (SNPs) in predicting treatment-induced hypertension (HTN) and clinical outcome (CO) in metastatic clear cell RCC (mccRCC) patients (pts) treated ...

Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This ...

Hopes had not exactly soared high for Regeneron Pharmaceuticals Inc.'s combo pairing the angiopoietin2 (Ang2) antibody nesvacumab with approved Eylea (aflibercept), although "nobody would like it to ...

Aging causes a reduction of the protein Tie2, a risk factor for increased intraocular pressure and glaucoma. In this experiment, one eye of mice lacking Ang1 and Ang2 was injected with the premixed ...

Regeneron acquired full exclusive rights to two families of antibodies invented at the company’s labs, but previously included in its antibody collaboration with Sanofi. Acquired by Regeneron were ...

A team of scientists from the United States and Sweden has recently demonstrated that increased levels of a proinflammatory cytokine, angiopoietin-2, is responsible for hypercoagulation observed in ...